Ellerston Australian Emerging Leaders Fund



Monthly Report as at 30 September 2024


APIR Code: ECL6748AU | ARSN 647 979 333



Portfolio of 30-60 smaller companies built through an active, research-driven investment approach.



Focus on companies which have a sound business franchise with an attractive earnings profile, which operate in growth industries and trade at a discount to valuation.



Performance Summary

| Performance | 1 Month | 3 Months | 1 Year | 3 Years (p.a.) | Since Inception (p.a.)^^ |
|------------------|---------|----------|--------|----------------|-----------------------------|
| Net [^] | 4.10% | 7.28% | 39.99% | 0.85% | 2.17% |
| Benchmark* | 5.06% | 6.53% | 18.79% | -0.57% | -0.71% |
| Alpha | -0.96% | 0.75% | 21.20% | 1.42% | 2.88% |

[^]The net return figure is calculated after fees & expenses, assuming all distributions are reinvested. Past performance is not a reliable indication of future performance.

Key Information

| Portfolio Manager(s) | David Keelan & Alexandra Clarke | | | |
|---|--|--|--|--|
| Investment Objective | To outperform the Benchmark over a rolling three year period. | | | |
| Benchmark | S&P/ASX Small Ordinaries Accumulation Index | | | |
| Liquidity | Daily | | | |
| Target Number of Holdings | 30-60 | | | |
| Number of Holdings at Month End | 42 | | | |
| Minimum Investment | Initial investment - \$10,000 Additional investment - \$5,000 | | | |
| Distribution Frequency | Half-Yearly (where available) | | | |
| Management Fee | 1.10% (p.a.) | | | |
| Performance Fee ¹ | 20.00% | | | |
| Buy/Sell Spread | 0.25% / 0.25% | | | |
| Of the investment return above the benchmark, after | | | | |


¹Of the investment return above the benchmark, after recovering any underperformance in past periods.

Top Holdings*

| Company | Sector | |
|------------------------------|------------------------|--|
| Codan Limited | Information Technology | |
| Generation Development Group | Financials | |
| Life360, Inc. | Information Technology | |
| Qoria Limited | Information Technology | |
| Zip Co Ltd. | Financials | |

^{*}In alphabetical order. Source: Ellerston Capital.

Sector Allocation



Source: Ellerston Capital.

1

^{*} S&P/ASX Small Ordinaries Accumulation Index. ^^Inception date is 13 August 2021.

Market Capitalisation Exposure



Key Portfolio Metrics

| FY25e | Fund | Benchmark |
|-----------------|--------|-----------|
| Price/Earnings | 18.66x | 20.33x |
| Dividend Yield | 2.50% | 3.10% |
| Net Debt/EBITDA | 0.04x | 1.41x |

Source: Ellerston Capital.

Source: Ellerston Capital.

COMMENTARY

The Ellerston Australian Emerging Leaders Fund delivered 4.10% (net) in September relative to the S&P/ASX Small Ordinaries Accumulation Index which returned 5.06%. September which is usually one of the weaker months of the year started off in-line with expectations, however, between a US rate cut (50bps) and significant China stimulus the market rallied strongly with energy and materials names some of the key beneficiaries. This saw a divergence between Small Industrials which were up 4.3% and Small Resources which finished up 7.2%.

Two names which performed well in September were Capital Health (CAJ AU) and Tuas Limited (TUA AU).

CAJ is a name that has been in the portfolio for a long period of time and gained 15.6% over the course of the month. It's a leading diagnostic imaging business with a footprint heavily weighted to Victoria and Western Australia. In June 2024, CAJ received an Indicative Proposal from Integral Diagnostics (IDX AU) to acquire 100% of CAJ shares at an implied valuation of \$0.326 at the time of proposal, or a 33% premium to the previous close price. Within September, CAJ had their Scheme Booklet approved by the courts and registered with ASIC, significantly lowering the risk that the merger does not proceed. As a result, we saw the gap between the implied takeover price and the current share price of CAJ narrow. In addition to this, the sector saw more M&A activity with Healius (HLS AU) selling their Lumus Imaging business to Affinity Equity Partners for an enterprise value of \$965m (c17x EBITDA) - supporting CAJ's valuation. We continue to hold CAJ as a core position with the fund and note that Scheme Meeting will take place on 31 October 2024.

TUA, a provider of mobile telecommunications services within Singapore, rallied 24.7% during the month on the back of their FY24 result. EBITDA was a solid beat versus consensus estimates, with strong operating leverage again a highlight. TUA mobile offering, now trading under the Simba brand, is now estimated to be 11% of the Singaporean market with little signs of slowing down. TUA is just at the beginning of its journey to replicate its success in Mobile to Broadband. Currently, there are 4,000 broadband with the ramp up in its 10Gbps offering only having begun recently. Although still very early days, the cross-sell opportunity coupled with competitive pricing and increasing brand awareness should continue to drive meaningful earnings growth. We continue to hold TUA as one of our core positions within the portfolio.

Looking to October, conference season is really warming up with numerous opportunities for companies to once again engage with the investment community and provide both qualitative and quantitative outlooks. As well as conferences, AGM season will start to kick off at the back end of October providing potentially further catalyst for stocks.

Find out more:

Contact Us

Sydney

Level 11, 179 Elizabeth Street, Sydney, NSW 2000 +612 9021 7701 info@ellerstoncapital.com Should investors have any questions or queries regarding the Fund, please contact our Investor Relations team on 02 9021 7701 or info@ellerstoncapital.com or visit us at

ellerstoncapital.com.

All holding enquiries should be directed to our registry, Automic Group $\,$

on 1300 101 595 or ellerstonfunds@automicgroup.com.au.

This report has been prepared by Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000 (Manager), as the responsible entity of the Ellerston Australian Emerging Leaders Fund ARSN 647 979 333 without taking account the objectives, financial situation or needs of individuals. Before making an investment decision about the Fund, persons should read the Fund's Product Disclosure Statement and Target Market Determination (TMD) which can be obtained from the Manager's website www.ellerstoncapital.com or by contacting info@ellerstoncapital.com and obtaining advice from an appropriate financial adviser. Units in the Fund are issued by Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000. This information is current as at the date on the first page.

This material has been prepared based on information believed to be accurate at the time of publication. Assumptions and estimates may have been made which may prove not to be accurate. Ellerston Capital undertakes no responsibility to correct any such inaccuracy. Subsequent changes in circumstances may occur at any time and may impact the accuracy of the information. To the full extent permitted by law, none of Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000, or any member of the Ellerston Capital Limited Group of companies makes any warranty as to the accuracy or completeness of the information in this newsletter and disclaims all liability that may arise due to any information contained in this newsletter being inaccurate, unreliable or incomplete. Past performance is not a reliable indicator of future performance.

